Phase 2 PIONEER Trial of Oral T3D‐959 for the Treatment of Patients Diagnosed with Mild‐to‐Moderate Alzheimer’s Disease: New Results in a Modified Intent‐to‐Treat Population... von Stanek, Jessica, Swearingen, Blake, Strittmatter, Warren, Chamberlain, Stan, Gabriel, Hoda, Coutlee, Christopher, Lineberry, Charles, Didsbury, John

Volltext

The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild... von Didsbury, John, Strittmatter, Warren, Chamberlain, Stan, Gabriel, Hoda

Volltext

The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild... von Didsbury, John, Strittmatter, Warren, Chamberlain, Stan, Gabriel, Hoda

Volltext

The PIONEER Study: A Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial of the Effects of T3D‐959 on Safety, Cognition, Function and Plasma Biomarkers in Mild... von Stanek, Jessica, Swearingen, Blake, Gabriel, Hoda, Strittmatter, Warren, Chamberlain, Stan, Didsbury, John

Volltext

Towards a more representative Alzheimer’s disease clinical trial: Ethnic differences in underlying pathology call for demographic consideration in drug label development von Anderson, Nicolas, Stanek, Jessica, Swearingen, Blake, Gabriel, Hoda, Strittmatter, Warren, Chamberlain, Stan, Didsbury, John

Volltext

O1‐12‐04: EFFECTS OF A PPAR DELTA/GAMMA AGONIST, T3D‐959, ON METABOLIC AND COGNITIVE FUNCTIONS IN MILD TO MODERATE ALZHEIMER'S DISEASE SUBJECTS von Didsbury, John, Gabriel, Hoda, Strittmatter, Warren, Chamberlain, Stan

Volltext

From the Right Side von Chamberlain, David, Wagon, Stan

Volltext